Cumberland Pharmaceuticals NASDAQ: CPIX reported third-quarter net income of $77.8 million, reflecting the sale of its commercial products to Apotex Health, and outlined plans to advance its lead drug candidate toward a regulatory submission for Duchenne muscular dystrophy-associated heart disease.
The quarter was Cumberland’s first following the July 1 closing of the transaction, under which it received $100 million in cash in exchange for integrating its commercial products and organization into Apotex’s U.S. branded business. Chief Executive Officer A.J. Kazimi said Cumberland has refocused its strategy on developing treatments, primarily for rare diseases.
The company also announced an initiative to evaluate commercialization and partnering opportunities for its drug candidates. Kazimi said Cumberland would work with its investment banking advisers on the effort.
Financial position after the transaction
Cumberland ended September with $80.6 million in cash and cash equivalents, up from $11.4 million at the end of 2025, Chief Financial Officer John Hamm said. Total assets rose to $114 million from $77 million, while liabilities fell to $41.6 million from $52.3 million. Shareholders’ equity increased to $72.5 million from approximately $25 million.
Hamm said Cumberland repaid its $5.2 million bank line of credit during the summer and had no debt at quarter-end. The company also expects to receive $11 million for inventory and transition services within 12 months of closing the Apotex transaction.
Hamm estimated that taxes associated with the transaction would be less than $1 million because of tax loss carryforwards and research and development tax credits. He put estimated net funding from the transaction, including the additional $11 million, at $108 million.
Third-quarter net income included the gain on the sale of the commercial products, as well as ongoing research and development and administrative expenses. Interest income was $0.8 million for the quarter. Hamm said revenue and expenses associated with the Apotex transaction are classified as discontinued operations, and Cumberland will no longer record revenue or related expenses from the legacy commercial brands.
The company funded a special dividend of $1.50 per share, totaling $22 million, during the third quarter. Hamm said Cumberland had begun implementing a board-authorized share repurchase initiative and that several board members had entered trading plans to increase their holdings.
Management projects that remaining cash will fund operations for more than five years. Kazimi also said the $11 million in expected inventory and transition-service payments, together with interest income, would more than cover operating expenses during the 12-month post-transaction period.
Duchenne application preparations
Cumberland is preparing a new drug application for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, a rare genetic disease that affects skeletal, heart and lung muscles. Kazimi said the company decided to submit the application following a pre-application meeting with the Food and Drug Administration in the fall.
The company is proposing its FIGHT DMD trial as the pivotal study for a traditional approval, supported by comparison data from two natural history databases. In the trial, high-dose ifetroban produced a 5.4 percentage point improvement in left ventricular ejection fraction compared with a control group combining placebo-treated patients and propensity score-matched natural history patients, Kazimi said. The reported p-value was 0.002.
The FDA granted rolling review of the planned submission, according to Kazimi. He said the application would include trial and safety data, manufacturing information and additional analyses requested by the agency, including data from the study’s open-label extension. Cumberland plans to announce both the start and completion of the rolling submission.
Ifetroban has received orphan drug, rare pediatric disease and fast-track designations for the program. The FDA has also conditionally accepted DYSCORBAN as the product’s proprietary name, Kazimi said.
Other clinical programs
Senior Vice President of Operations Todd Anthony said ifetroban was generally well tolerated in the phase IIa ASSIST-SSc trial in systemic sclerosis, with no serious adverse events related to the study drug during the 12-month period. The trial was not designed or powered to evaluate efficacy. Cumberland plans to submit the clinical study report to the FDA and complete additional biomarker and cardiac imaging evaluations before deciding on further development.
In idiopathic pulmonary fibrosis, an independent committee reviewing safety data from the first group of patients to complete 12 weeks of treatment found no new safety signals and recommended no changes to study conduct, Anthony said. Enrollment continues, with interim efficacy results expected as the next milestone.
Anthony also discussed a phase II study conducted with Vanderbilt Health in patients with high-risk solid tumors. He said the trial met its primary safety endpoint and showed fewer metastatic recurrences and metastasis-related deaths in the ifetroban group than in the placebo group. Cumberland and Vanderbilt are developing plans for a follow-up study focused on selected cancer types.
Kazimi said Cumberland retained majority ownership of Cumberland Emerging Technologies, a venture founded with Vanderbilt University and Tennessee’s Launch Tennessee to advance biomedical discoveries from academic institutions.
About Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company headquartered in Nashville, Tennessee. The company develops, acquires and commercializes prescription medicines, with a focus on products that address unmet needs in critical care, gastroenterology, pain management and other specialty areas. Its portfolio has included Caldolor (ibuprofen injection), Acetadote (acetylcysteine injection), Kristalose (lactulose for oral solution), Vaprisol (conivaptan hydrochloride injection) and Omeclamox-Pak, a treatment for certain Helicobacter pylori infections.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
